Cava Group, Inc. logo is displayed on a smartphone screen

CAVA's Per-Restaurant Stock Value Outshines Chipotle's

Cava Group, Inc. logo is displayed on a smartphone screen

Markets are now looking more into shares of CAVA Group Inc. (NYSE: CAVA), not because it’s small but because it’s growing. Most seeking consumer discretionary sector opportunities may try to copy one of Wall Street’s sweethearts: Bill Ackman. Through his hedge fund, Pershing Square, Ackman decided that Chipotle Mexican Grill Inc. (NYSE: CMG) was worth his investors’ capital.

The problem for smaller retail investors lies in timing and size. Chipotle has now had an incredible run, outperforming the broader S&P 500 by over 6,000% since its initial public offering (IPO) in 2006, bringing the company’s market capitalization up to $89.9 billion. With earnings per share (EPS) projections set at 20.3% growth for the next 12 months, Chipotle is still considered a growth stock but not as attractive as CAVA has become.

Following the same business model, with its menu being one of the few differences, CAVA gives investors a path to follow in Chipotle’s footsteps and potentially deliver a couple of thousand percentage points of return for those investors willing to stick with it in the long run.

CAVA's Second Generation Success: Lessons Learned from Chipotle's Mistakes

Chipotle’s massive growth may have been a blessing, but as every Wall Streeter knows, there are no free lunches. The company’s growth came with a cost, and customers were handed the bill to pay.

The company’s quick growth made it hard to keep operations and other quality measures airtight, which is why Chipotle has been subject to several health complaints, which haven’t improved over the years. The most notable of these accusations came in 2015 when Chipotle was accused of being responsible for E. coli outbreaks.

But that wasn’t all 2015 had in store. Norovirus and Salmonella accompanied E.coli that year; once washed out of Chipotle’s system, these food-borne illnesses returned in 2017 and 2018. Even after these sour years, Chipotle still falls short in several other metrics.

In January 2024, Chipotle fell behind in the chlorine levels measured in its dish machine. This mistake could escalate into bacterial growth and other risks for the company’s location. Here’s how CAVA has learned from its predecessor’s mistakes.

Early profits for CAVA have one focus in mind for management: to reward shareholders in any way possible. Up to $35 million were deployed into a new Virginia-based facility, which focuses on the latest pasteurization technology to retain the brand's sanitation and quality standards as high as possible.

Conscious Investments at CAVA: Driving High Market Regard and Investor Confidence

This level of consciousness by management allowed the stock to drive its key performance indicators (KPIs) beyond peers like Chipotle.

On a per-restaurant basis, CAVA is now worth $30.3 million, above Chipotle’s $24.7 million. This significant discrepancy underscores how vital CAVA’s growth is and has been. Because CAVA is only a $10.3 billion company, a $70 billion blow to Chipotle can allow investors to tap into a multi-year life-changing run.

Wall Street analysts expect the company to see EPS growth of 35.3% in the next 12 months, above Chipotle's 20.3% projections. However, are there any reasonable factors that can justify the company's rapid pace of future growth?

Looking at past history can help investors understand why these analysts have become so bullish about CAVA's future. CAVA's first quarter 2024 earnings results show a 30.3% jump in net revenue. This figure drove the company's first-ever positive free cash flow (operating cash flow minus capital expenditures) of $4.7 million.

When newer companies hit the positive free cash flow mark, they tend to command higher regard from investors looking for a value deal. CAVA’s latest figure is likely to keep growing. What drives more free cash flow? Scale, and speaking of which, CAVA grew its restaurant count by 14 over the quarter and by 60 over the year.

Because CAVA is now worth much more per restaurant than Chipotle, the only way to normalize this metric is to boost the number of CAVA locations. Knowing this, management boosted its 2024 guidance regarding restaurant openings, where a prior 48-52 range looks more like 50-54 today.

More than that, management boosted its expected restaurant profit level up 23.7% to 24.3%. These profit margins aid in the stock’s path to match Chipotle’s return on invested capital (ROIC) rate of 15.1%, while CAVA’s ROIC grew to 2% from negative 5.2% in 2022.  

Learn more about CMG

Newest Stories

In the System Control Room Technical Operator Works at His Workstation with Multiple Displays Showing Graphics
This Cybersecurity Stock Gains Analysts' Favor for Strong Growth

As the global economy becomes more digitized by the day, business and customer data are kept in what’s now the most common term in the technology sector: The Cloud. Companies rely on cloud computing services and artificial intelligence to make the vast databases they can access work for them...

Gabriel Osorio-Mazilli | Jul 18, 2024

Mechanic in blue workwear uniform inspects the car bottom with his assistant. Automobile repairing service
Parabolic Rise of This Stock Shows No Signs of Slowing

Cintas Corporation’s (NASDAQ: CTAS) Q4 results and guidance prove its parabolic share price movement can continue. The results continue a trend that includes organic and acquisitional growth, widening margins, robust cash flow, and capital returns. The trend has the stock price up more tha...

Thomas Hughes | Jul 18, 2024

Photo of an artistic drawing of two heads showing one with gears (representing facts) and one with clouds (representing emotions) to illustrate the concepts of risk tolerance and risk appetitie.
Risk Tolerance vs. Risk Appetite: Key Differences

Risk tolerance and risk appetite may sound like different ways to describe the same thing, but they’re actually very distinct measurements. Risk tolerance ensures that you do not take on more risk than you can emotionally handle, preventing stress and impulsive decisions, while risk appetite h...

Dan Schmidt | Jul 18, 2024

close up. scientists are testing a new vaccine . photo with copy - space.
Why This Leading Health Stock is a Buy No Matter the Market Move

Abbott  Laboratories (NYSE: ABT) is a premier buy-and-hold stock because of its foresightful management, quality operation, portfolio, pipeline, cash flow, and capital return. It’s not always a good buy; all healthcare stocks have ups and downs in their cycles, but Abbott is a buy today...

Thomas Hughes | Jul 18, 2024

TickerTalk Unveils Real-Time Financial Insights and Breaking News!